Tiziana Life Sciences Ltd (TLSA) Form 6-K — Sep 21, 2026
Tiziana Life Sciences (Nasdaq: TLSA) announced that the last patient has completed their last visit in its Phase 2a INFORM-MS trial evaluating intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS), clearing the way for a topline readout. The randomized, double-blind, placebo-controlled study enrolled 48 patients across three cohorts at multiple leading U.S. clinical sites, testing two intranasal doses versus placebo over a 12-week treatment period. The primary endpoint is change in microglial activation measured by PET imaging, with EDSS and the Modified Fatigue Impact Scale as secondary clinical endpoints.
Key figures
- Cohorts
- 3
- Trial Nct Id
- NCT06292923
- Patients Enrolled
- 48
- Expanded Access Nct Id
- NCT06802328
- Treatment Period Weeks
- 12
- Open Label Extension Duration
- 6 months
- Expanded Access Patients Dosed
- 14
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.